Company Revenue Reports

The company's orthopedic revenues for its fiscal fourth quarter fell -35% as it endured an additional month of COVID-related impact in April compared to competitors.

The company grew in FY19 despite COVID-related declines in its fourth quarter, driven by both reimbursement wins and competitive account conversions.

The company was able to offset deeper COVID-related declines on the strength of its advanced DBM portfolio and plans to pursue several alpha launches of new products in 2020.

Geographic factors and a highly elective portfolio exposed the company to a severe downturn due to COVID-19, with 1Q20 revenue down 20% and April revenues down 95%.

While the company's orthopedic revenues declined in the high single-digits in 1Q20, Zimmer Biomet's balance sheet and cost containment measures will allow it to aggressively pursue key R&D initiatives.

The company's orthopedic business declined in mid-single digits for 1Q20, with a precipitous -80% decline in April. However, Integra expects the market to right itself by year-end.

The company's sales declined in the mid-single digits in 1Q20, but included a few bright spots like continuing adoption of the M6-C artificial disc.

The company's late-2019 growth momentum continued for most of 1Q20, resulting in nearly 22.6% growth. ATEC is confident the spine market will be one of the first to rebound from COVID-19.

The company was on pace to deliver double-digit growth in 1Q20 before COVID-related surgical delays, and procedures were down roughly 90% in April.

The company's 1Q20 growth amid COVID-19 was fueled by $6.8 million in sales from Parcus and Arthosurface, in addition to continuing purchase orders of legacy viscosupplements.